Your browser doesn't support javascript.
loading
Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1.
Jutant, Etienne-Marie; Jaïs, Xavier; Girerd, Barbara; Savale, Laurent; Ghigna, Maria-Rosa; Perros, Frédéric; Mignard, Xavier; Jevnikar, Mitja; Bourlier, Delphine; Prevot, Grégoire; Tromeur, Cécile; Bauer, Fabrice; Bergot, Emmanuel; Dauphin, Claire; Favrolt, Nicolas; Traclet, Julie; Soumagne, Thibaud; De Groote, Pascal; Chabanne, Céline; Magro, Pascal; Bertoletti, Laurent; Gueffet, Jean-Pierre; Chaouat, Ari; Goupil, François; Moceri, Pamela; Borie, Raphael; Fadel, Elie; Wolkenstein, Pierre; Brillet, Pierre-Yves; Simonneau, Gérald; Sitbon, Olivier; Humbert, Marc; Montani, David.
Afiliação
  • Jutant EM; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Jaïs X; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Girerd B; Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • Savale L; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Ghigna MR; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Perros F; Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • Mignard X; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Jevnikar M; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Bourlier D; Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • Prevot G; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Tromeur C; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Bauer F; Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • Bergot E; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Dauphin C; Service d'Anatomopathologie, and.
  • Favrolt N; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Traclet J; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Soumagne T; Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • De Groote P; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Chabanne C; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Magro P; Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • Bertoletti L; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Gueffet JP; INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies.
  • Chaouat A; Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • Goupil F; Service des Maladies Respiratoires, Hôpital Haut-Lévêque CHU Bordeaux Pessac, France.
  • Moceri P; Pneumologie et Maladies Rares, Pôle Voies Respiratoires, Hôpital Larrey, Toulouse, France.
  • Borie R; Service de Pneumologie, Hôpital de la Cavale Blanche, Brest, France.
  • Fadel E; INSERM U1096, Heart Failure Clinic and Pulmonary Hypertension Center, Rouen, France.
  • Wolkenstein P; Service de Chirurgie Cardiaque, Hôpital Charles Nicole, Rouen, France.
  • Brillet PY; Service de Pneumologie et Oncologie Thoracique, CHU Côte de Nacre, Caen, France.
  • Simonneau G; Service de Cardiologie et Maladies Vasculaires, Hôpital Gabriel Montpied, Clermont Ferrand, France.
  • Sitbon O; Service de Pneumologie et Soins Intensifs Respiratoires, CHU François Mitterrand, Dijon, France.
  • Humbert M; Service de Pneumologie, Hôpital Louis Pradel, Lyon, France.
  • Montani D; Service de Pneumologie, Hôpital Minjoz, Besançon, France.
Am J Respir Crit Care Med ; 202(6): 843-852, 2020 09 15.
Article em En | MEDLINE | ID: mdl-32437637
Rationale: Pulmonary hypertension (PH) associated with neurofibromatosis type 1 (NF1) is a rare and largely unknown complication of NF1.Objectives: To describe characteristics and outcomes of PH-NF1.Methods: We reported the clinical, functional, radiologic, histologic, and hemodynamic characteristics, response to pulmonary arterial hypertension (PAH)-approved drugs, and transplant-free survival of patients with PH-NF1 from the French PH registry.Measurements and Main Results: We identified 49 PH-NF1 cases, characterized by a female/male ratio of 3.9 and a median (minimum-maximum) age at diagnosis of 62 (18-82) years. At diagnosis, 92% were in New York Heart Association functional class III or IV. The 6-minute-walk distance was 211 (0-460) m. Pulmonary function tests showed low DlCO (30% [12-79%]) and severe hypoxemia (PaO2 56 [38-99] mm Hg). Right heart catheterization showed severe precapillary PH with a mean pulmonary artery pressure of 45 (10) mm Hg and a pulmonary vascular resistance of 10.7 (4.2) Wood units. High-resolution computed tomography images revealed cysts (76%), ground-glass opacities (73%), emphysema (49%), and reticulations (39%). Forty patients received PAH-approved drugs with a significant improvement in functional class and hemodynamic parameters. Transplant-free survival at 1, 3, and 5 years was 87%, 54%, and 42%, respectively, and four patients were transplanted. Pathologic assessment showed nonspecific interstitial pneumonia and major pulmonary vascular remodeling.Conclusions: PH-NF1 is characterized by a female predominance, a low DlCO, and severe functional and hemodynamic impairment. Despite a potential benefit of PAH treatment, prognosis remains poor, and double-lung transplantation is an option for eligible patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibromina 1 / Hipertensão Pulmonar / Neoplasias Pulmonares Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Am J Respir Crit Care Med Assunto da revista: TERAPIA INTENSIVA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibromina 1 / Hipertensão Pulmonar / Neoplasias Pulmonares Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Am J Respir Crit Care Med Assunto da revista: TERAPIA INTENSIVA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França